INS and Hypoglycemia: Since a low potential has been reported for hypoglycemia and 55P0110 has proven to be as effective as current established oral antidiabetic drugs, next studies are expected to focus on its mechanism of action, i.e., whether the action of this new compound involves effects on membrane or nuclear receptors of pancreatic β-cells, such as GLPR1, GIPR and GPR40, and/or on their endogenous agonists, thus potentiating glucose-induced insulin secretion [69].